Shopping Cart
- Remove All
- Your shopping cart is currently empty
Caldaret is an intracellular Ca2+ handling modulator that acts through reverse mode Na+/Ca2+ exchanger inhibition.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $521 | 6-8 weeks | |
25 mg | $1,230 | 6-8 weeks | |
50 mg | $1,610 | 6-8 weeks | |
100 mg | $1,990 | 6-8 weeks |
Description | Caldaret is an intracellular Ca2+ handling modulator that acts through reverse mode Na+/Ca2+ exchanger inhibition. |
In vitro | Caldaret resume Ca2+-ATPase activity of the sarcoplasmic reticulum isolated from the myocardium acutely exposed to ischemia and reperfusion in vitro [2]. |
In vivo | Caldaret (MCC-135) has beneficial effects in heart failure. In diabetic rats, Caldaret decreases TR80 significantly without a significant effect on developed tension (DT). Caldaret has minimal effects on SR Ca2+ uptake in normal rats, which is observed as increased SR Ca2+ uptake at uptake time of 20 and 30 s at the highest concentration of 10 μM. In diabetic rats, Caldaret increases SR Ca2+ uptake all over the range of uptake time. Both the initial rate of SR Ca2+ uptake and the amount of Ca2+ accumulated in the SR with longer uptake time are increased by Caldaret [2]. Caldaret limits the infarct size of the reperfused canine heart. The amelioration of intracellular Ca2+ handling dysfunction achieved by Caldaret leads to cardioprotective effects against reperfusion injury following prolonged ischemia [1]. |
Alias | MCC-135 |
Molecular Weight | 256.32 |
Formula | C11H16N2O3S |
Cas No. | 133804-44-1 |
Relative Density. | 1.302g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.